Frazier Life Sciences Acquisition Corp. II (FLSC): Entry into a Material Definitive Agreement
Frazier Life Sciences Acquisition Corp. II (FLSC) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Frazier Life Sciences Acquisition Corp. II Announces Pricing of $75,000,000 Initial Public Offering Palo Alto, CA, October 13, 2026 – Frazier Life Sciences Acquisition Corp. II (the “Company”), a special purpose acquisition company, announced today that it priced its
- Instrument
- Class A ordinary shares
- Shares
- 7,500,000 Class A ordinary shares
- Price per share
- $10.00 per share
- Gross proceeds
- $75,000,000
Facts are quoted from the filing text and checked against it.
How this was made
The 30-second read
Why it matters
This 8-K primarily updates investors on IPO pricing, share count, offering size, and the expected close and first trading date under ticker FLSC.
Market read
The disclosure is actionable for near-term trading around the IPO close and first trading day, but it does not provide a target acquisition or valuation guidance beyond the offering terms.
What to watch
Traders may need to monitor post-close capital structure details (trust terms, redemption mechanics) and any subsequent 8-K updates for deal timelines, which are not included here.
Background
The company is a SPAC formed to pursue a business combination, with management focused on biotechnology opportunities.
Ticker impact
Frazier Life Sciences Acquisition Corp. II priced a $75,000,000 IPO of 7,500,000 Class A shares at $10.00, listing on Nasdaq as FLSC.
Likely initial volatility around the first trading day as the market prices the SPAC structure and IPO proceeds, with direction dependent on broader SPAC sentiment.
The filing discloses the IPO terms (size, share count, price) and the Nasdaq ticker start date, but provides no deal target or redemption details that would anchor valuation beyond listing mechanics.
Market effects
Adds a new biotech-focused SPAC to the market, which can marginally affect near-term SPAC supply/demand and biotech-SPAC sentiment.
Primarily US-listed Nasdaq flow impact; limited spillover beyond US SPAC/biotech investor base.
Low, as the event is US IPO mechanics with no cross-border deal or regulatory action described.
Counterpoint
IPO pricing alone may not sustain performance if redemption risk or lack of a near-term target deal becomes the dominant narrative.
Key entities
- companyFrazier Life Sciences Acquisition Corp. II
SPAC that priced its initial public offering and will trade on Nasdaq under ticker FLSC.
- financial_advisorJefferies LLC
Sole book-running manager for the IPO.
